Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

National study benchmarks pancreatic cancer surgery outcomes across China

Pancreatic cancer is among the most aggressive malignancies, and in China it accounts for a substantial and rising share of cancer deaths.

25 Sep 2026

MIT researchers build cell collection device for early cancer detection

One of the main reasons that ovarian cancer is among the deadliest forms of cancer is timing: When doctors catch it early, the five-year survival rate can be north of 90 percent.

24 Sep 2026

UVA study evaluates safety and real-world outcomes of histotripsy

UVA Health researchers have reviewed patient outcomes from a new, noninvasive way to treat liver tumors called histotripsy and concluded that while the procedure was associated with low rates of laboratory toxicity and procedural complications, the findings highlight the need to better define which patients are most likely to benefit.

23 Sep 2026

Scientists reveals how cancer-causing p53 mutations remain invisible to the immune system

One of the biggest challenges in cancer immunotherapy may not be that immune cells are too weak, but that some tumors give them too little to see.

17 Sep 2026

Simple fecal test could help detect colorectal and pancreatic cancers

Gastrointestinal and pancreatobiliary cancers can be difficult to detect early, creating a need for practical, noninvasive approaches for early detection and risk assessment.

16 Sep 2026

New AACR report outlines future of cutting-edge cancer research

Today, the American Association for Cancer Research (AACR) released the 16th edition of its annual Cancer Progress Report.

16 Sep 2026

Novel blood test could detect pancreatic cancer at its earliest stages

Researchers at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the country, led the development of a new, investigational blood test that could detect pancreatic cancer at its earliest stages, when the disease is more treatable and potentially curable.

16 Sep 2026

Laser therapy offers new hope for inoperable pancreatic tumors

UCI Health, the clinical enterprise of the University of California, Irvine, is conducting a first-in-human, phase 1 clinical trial using laser light to target localized but inoperable pancreatic tumors to help patients become cancer free.

10 Sep 2026

New genetic map helps track aggressive prostate cancer development

Prostate cancer is the second most common form of cancer among men globally. Yet, we still know relatively little about why the disease develops or why some men live with it for years while in others it progresses aggressively.

9 Sep 2026

Is stroke risk higher after a cancer diagnosis?

New research indicates that people with invasive cancer face an elevated risk of experiencing a stroke, especially in the first few months after diagnosis and especially if they have certain types of cancer.

9 Sep 2026

Daraxonrasib shows durable responses in RAS-mutant lung cancer

Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC) in a Phase 1/2 trial led by The University of Texas MD Anderson Cancer Center.

2 Sep 2026

Early-onset bowel cancer shows distinct biological and clinical features

One of Australia's largest real world studies of younger adults with advanced bowel cancer has identified important differences between cancers diagnosed before and after the age of 50, which could help doctors tailor treatments for younger adults more effectively.

1 Sep 2026

FDA approves daraxonrasib for patients with metastatic pancreatic cancer

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib for patients whose pancreatic cancer has spread to other parts of the body and continued to progress despite previous treatment.

29 Aug 2026

FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

From Dana-Farber Cancer Institute, Inc. 29 Aug 2026